Avalyn Pharma Inc. Common Stock AVLN
i
Market datapartial · fetched 2026-11-03T19:09:44.702Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-03T19:06:41.151724154Z
FundamentalsAlpha Vantage · unavailable
Avalyn Pharma Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 23.02 | 76.9% | 14.1% | |||
| 25Δ | 29.81 | 77.0% | 16.3% | 23.67 | 75.7% | 12.3% |
| 30Δ | 29.20 | 76.6% | 14.8% | 24.32 | 74.5% | 10.5% |
| 35Δ | 28.60 | 76.2% | 13.2% | 24.97 | 73.3% | 8.7% |
| 40Δ | 27.99 | 75.8% | 11.7% | 25.57 | 73.5% | 7.8% |
| 45Δ | 27.39 | 75.4% | 10.2% | 26.17 | 73.8% | 7.0% |
| 50Δ | 26.78 | 74.9% | 8.7% | 26.76 | 74.1% | 6.2% |
| 55Δ | 26.18 | 74.5% | 7.2% | 27.36 | 74.4% | 5.4% |
| 60Δ | 25.57 | 74.1% | 5.7% | 27.96 | 74.7% | 4.6% |
| 65Δ | 24.96 | 73.8% | 4.3% | 28.55 | 75.0% | 3.8% |
| 70Δ | 24.29 | 75.7% | 3.6% | 29.15 | 75.2% | 3.0% |
| 75Δ | 23.62 | 77.5% | 2.9% | 29.74 | 75.5% | 2.1% |
| 80Δ | 22.94 | 79.4% | 2.3% | 33.83 | 96.7% | 1.6% |
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 23.02
- IV
- 76.9%
- B/E move
- 14.1%
25Δ
- Pseudo strike
- 29.81
- IV
- 77.0%
- B/E move
- 16.3%
- Pseudo strike
- 23.67
- IV
- 75.7%
- B/E move
- 12.3%
30Δ
- Pseudo strike
- 29.20
- IV
- 76.6%
- B/E move
- 14.8%
- Pseudo strike
- 24.32
- IV
- 74.5%
- B/E move
- 10.5%
35Δ
- Pseudo strike
- 28.60
- IV
- 76.2%
- B/E move
- 13.2%
- Pseudo strike
- 24.97
- IV
- 73.3%
- B/E move
- 8.7%
40Δ
- Pseudo strike
- 27.99
- IV
- 75.8%
- B/E move
- 11.7%
- Pseudo strike
- 25.57
- IV
- 73.5%
- B/E move
- 7.8%
45Δ
- Pseudo strike
- 27.39
- IV
- 75.4%
- B/E move
- 10.2%
- Pseudo strike
- 26.17
- IV
- 73.8%
- B/E move
- 7.0%
50Δ
- Pseudo strike
- 26.78
- IV
- 74.9%
- B/E move
- 8.7%
- Pseudo strike
- 26.76
- IV
- 74.1%
- B/E move
- 6.2%
55Δ
- Pseudo strike
- 26.18
- IV
- 74.5%
- B/E move
- 7.2%
- Pseudo strike
- 27.36
- IV
- 74.4%
- B/E move
- 5.4%
60Δ
- Pseudo strike
- 25.57
- IV
- 74.1%
- B/E move
- 5.7%
- Pseudo strike
- 27.96
- IV
- 74.7%
- B/E move
- 4.6%
65Δ
- Pseudo strike
- 24.96
- IV
- 73.8%
- B/E move
- 4.3%
- Pseudo strike
- 28.55
- IV
- 75.0%
- B/E move
- 3.8%
70Δ
- Pseudo strike
- 24.29
- IV
- 75.7%
- B/E move
- 3.6%
- Pseudo strike
- 29.15
- IV
- 75.2%
- B/E move
- 3.0%
75Δ
- Pseudo strike
- 23.62
- IV
- 77.5%
- B/E move
- 2.9%
- Pseudo strike
- 29.74
- IV
- 75.5%
- B/E move
- 2.1%
80Δ
- Pseudo strike
- 22.94
- IV
- 79.4%
- B/E move
- 2.3%
- Pseudo strike
- 33.83
- IV
- 96.7%
- B/E move
- 1.6%
Options history
Table
| Date | IV (%) |
|---|---|
| 59.54% | |
| 60.01% | |
| 59.44% | |
| 61.16% | |
| 77.81% | |
| 79.70% | |
| 79.18% | |
| 71.43% | |
| 84.78% |
Biotechnology
AVTX
Avalo Therapeutics Inc is a forward-thinking clinical-stage biotechnology company focused on developing transformative therapies for rare and underserved diseases, particularly…
More →AVXL
Anavex Life Sciences Corp. The company is headquartered in New York, New York.
More →AXSM
Axsome Therapeutics, Inc., a biopharmaceutical company, is dedicated to developing new therapies for central nervous system (CNS) disorders in the United States. The company is…
More →BBIO
BridgeBio Pharma, Inc. is dedicated to the discovery, development and supply of various drugs for genetic diseases. The company is headquartered in Palo Alto, California.
More →BCAX
Description unavailable
More →BCYC
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, is developing a class of drugs for diseases that are not served by existing treatments. The company is…
More →